A PHASE II STUDY OF MOTEXAFIN-GADOLINIUM (NSC 695238, IND 55583) AND INVOLVED FIELD RADIATION THERAPY FOR INTRINSIC PONTINE GLIOMA OF CHILDHOOD

Trial Profile

A PHASE II STUDY OF MOTEXAFIN-GADOLINIUM (NSC 695238, IND 55583) AND INVOLVED FIELD RADIATION THERAPY FOR INTRINSIC PONTINE GLIOMA OF CHILDHOOD

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2014

At a glance

  • Drugs Motexafin gadolinium (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 May 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top